TEVA PHARMACEUTICAL INDUSTRIES LIMITED (TEVA) /
The cash flow of TEVA PHARMACEUTICAL INDUSTRIES LIMITED over the past 10 years
Chart TEVA PHARMACEUTICAL INDUSTRIES LIMITED: operating cash flow, capital expenditures, free cash flow, fiscal 2016–2025 Open the chart →In fiscal 2025, the latest fiscal year on file, TEVA PHARMACEUTICAL INDUSTRIES LIMITED's operating cash flow was $1.65B and its capital expenditures $501M, leaving free cash flow of $1.15B. Free cash flow was above zero in all 10 years shown. It ranged from $223M in fiscal 2019 to $2.99B in fiscal 2016. Capital expenditures were highest in fiscal 2016, at $901M.
Year by year
| Fiscal year | Operating cash flow | Capital expenditures | Free cash flow* |
|---|---|---|---|
| 2025ended Dec 31, 2025 | $1.65B | $501M | $1.15B |
| 2024ended Dec 31, 2024 | $1.25B | $498M | $749M |
| 2023ended Dec 31, 2023 | $1.37B | $526M | $842M |
| 2022ended Dec 31, 2022 | $1.59B | $548M | $1.04B |
| 2021ended Dec 31, 2021 | $798M | $562M | $236M |
| 2020ended Dec 31, 2020 | $1.22B | $578M | $638M |
| 2019ended Dec 31, 2019 | $748M | $525M | $223M |
| 2018ended Dec 31, 2018 | $2.45B | $651M | $1.79B |
| 2017ended Dec 31, 2017 | $2.23B | $874M | $1.35B |
| 2016ended Dec 31, 2016 | $3.89B | $901M | $2.99B |
Fiscal years as TEVA PHARMACEUTICAL INDUSTRIES LIMITED reports them. * Calculated by us from the company's filed figures; — no figure on file. From SEC filings, updated nightly. How each line is read.
More on TEVA PHARMACEUTICAL INDUSTRIES LIMITED
- The revenue of TEVA PHARMACEUTICAL INDUSTRIES LIMITED
- The profitability of TEVA PHARMACEUTICAL INDUSTRIES LIMITED
- All of TEVA PHARMACEUTICAL INDUSTRIES LIMITED's financials, charted
Companies of a similar size
- WABWESTINGHOUSE AIR BRAKE TECHNOLOGIES CORPORATION
- AMPAMERIPRISE FINANCIAL, INC.
- XYZBlock, Inc.
- MNSTMonster Beverage Corp
- CIENCiena Corp
Not investment advice. This page shows what TEVA PHARMACEUTICAL INDUSTRIES LIMITED filed with the SEC. Nothing here is a recommendation about any security. Check important figures against the company's own filings.